Tyrosine Kinase Inhibitors Significantly Reduce AML Transformation Risk in Systemic Mastocytosis with Associated Myeloid Neoplasms

Highlight

This international registry study demonstrates that treatment with KIT D816V-selective tyrosine kinase inhibitors (TKIs) in patients with systemic mastocytosis associated with a myeloid neoplasm (SM-AHN) is associated with significantly longer overall survival and substantially lower incidence of acute myeloid leukemia (AML) transformation at 36 months.

Study Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply